Overall verdict
Neutral
6.4/10
1-year performance
+11.58%
Score breakdown
Up 11.6% over 1 year, 76% of the 52-week range.
Strongest: Profitability 8.0/10. Weakest: Shareholder return 4.6/10.
22 analysts, target +0.1% vs the price.
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).
The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products.
The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries.
The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nasdaq
United States
CEO
Peter Arduini
Founded
2022
Employees
54 000
Revenue / employee
381 944 USD
Next earnings
February 5, 2027 (estimated)
Institutional holders
- GEODE CAPITAL MANAGEMENT, LLC2.86%
- FMR LLC0.96%
- Bank of New York Mellon Corp0.58%
- Rest of the register95.60%
3 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
89.77 USD
52-week low
58.75 USD
1-year performance
11.58%
Rising
Year-to-date performance
-0.42%
Rising
Drawdown
-8.39%
Mild pullback
Position in the 52-week range
76% of range
Range: 75.00 USD - 100.00 USD (2 methods agree)
The price implies growth of 4.79% per year; the company grows at 0.61%.
Gross margin 39.7%, net margin 10.0%, ROIC 10.6%, ROE 19.9%.
Net margin
9.95%
Fair
Sector 9.11%|S&P 13.40%
Gross margin
39.65%
Low
Return on equity (ROE)
19.93%
Exceptional
Sector 7.42%|S&P 17.06%
Return on invested capital (ROIC)
10.63%
Exceptional
Free cash flow margin (FCF)
8.73%
Fair
Profit-to-cash conversion (FCF conversion)
0.88x
Fair
Margin stability
1.4 pts
Very steady
Revenue to net income
Growth
5.5/10Revenue up 7.2% over 1 year, 3.7% a year over 5, EPS 0.6% a year over 5.
Revenue (trailing 12 months)
21.6Md USD
Revenue growth (1y)
7.19%
Moderate
Revenue growth (3y)
12.45%
Moderate
EPS growth (1y)
39.11%
Hyper-growth
EPS CAGR (5y)
0.61%
Low
EPS revisions (3 months)
1.91%
Revised up
Valuation
4.9/10P/E 17.4x, forward P/E 16.7x, EV/EBITDA 12.1x, PEG 28.46. The multiple sits in the 56th percentile of its own 5-year history.
P/E (TTM)
17.4x
Cheap
Sector 29.3x|S&P 23.6x
Forward P/E
16.7x
Fair
EV / EBITDA
12.1x
Fair
Sector 14.4x|S&P 15.5x
PEG
28.46
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
82.98 USD
Fairly priced
P/E vs its own 5-year history
among the 44% highest valuations
In line with its history
Market cap
37.2Md USD
Financial strength
6.6/10Cash covers 27.4% of the debt, net debt/EBITDA 1.7x.
Net debt / EBITDA
1.7x
Tight
Gearing (net debt / equity)
63.66%
Tight
Cash
2.9Md USD
Cash / market cap
7.68%
Tight
Cash / total debt
27.42%
Tight
Interest coverage
5.9x
Solid
Net debt
7.6Md USD
Equity
11.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 83.65 USD
- MM2075.60
- MM5069.82
- MM20069.89
- RSI 1472.6
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.23%
200-day average slope, 3 months
-4.19%
50-day average slope, 1 month
+1.68%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.47 % per day
Volatility change
+17.66%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 4.92 (11) | 5.02 (22) | 21 864 (21) | 3 955 (15) | 2 244 (11) |
| 2027 | 5.20 (11) | 5.50 (20) | 22 928 (18) | 4 236 (13) | 2 393 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 11, 2026.
Same sub-industry: 187 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SYK | 6.5 | 6.1 | 121Md USD | 34.0x | 13.8 % | 7.6 % | 9.7 % | 1.7x | 3.8 % | -10.5 % | ||
| 2 | GEHC | 6.4 | 6.0 | 37.2Md USD | 17.4x | 10.0 % | 7.2 % | 10.6 % | 1.7x | 5.1 % | 11.6 % | ||
| 3 | IDXX | 6.3 | 5.7 | 55.4Md USD | 47.4x | 25.4 % | 9.9 % | 54.9 % | 0.5x | 2.3 % | -1.2 % | ||
| 4 | ISRG | 6.2 | 5.5 | 156Md USD | 54.4x | 25.5 % | 21.7 % | 18.0 % | -1.6x | 2.3 % | -21.8 % | ||
| 5 | MDT | 6.2 | 6.7 | 130Md USD | 25.0x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 4.7 % | 9.3 % | ||
| 6 | ABT | 6.0 | 5.2 | 189Md USD | 40.3x | 9.8 % | 14.5 % | 6.6 % | 0.5x | 3.6 % | -13.7 % | ||
| 7 | EW | 5.9 | 5.1 | 60.8Md USD | 61.6x | 14.9 % | 10.5 % | 8.9 % | -2.0x | 2.3 % | 25.3 % | ||
| 8 | BSX | 5.6 | 6.4 | 65.4Md USD | 19.1x | 16.6 % | 1.4 % | 9.8 % | 1.8x | 5.1 % | -55.5 % | ||
| 9 | BDX | 5.5 | 5.3 | 58.4Md USD | 51.8x | 7.4 % | -10.5 % | 3.6 % | 2.9x | 4.6 % | 49.4 % |
